Astellas Backed By Full Pipeline To Battle Japan Price Controls And Slow U.S. Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
Tokyo-based firm reports net sales of ¥765.2 billion ($7.18 billion) for the 2008 third quarter compared to ¥702.5 billion ($6.59 billion) in the same quarter of 2007.
You may also be interested in...
Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients
Extended FDA review period up soon for long-lasting Prograf in liver transplant patients.
Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients
Extended FDA review period up soon for long-lasting Prograf in liver transplant patients.
Astellas Taps Pfizer Exec To Run New Global Development HQ
Long-time Pfizer exec Steven Ryder will become president of Astellas Pharma's new headquarters for global development in Deerfield, Ill., effective April 1, the Tokyo-based company announced March 4